{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:30:04Z","timestamp":1791271804846,"version":"4.1.0"},"reference-count":5,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2002,12,11]],"date-time":"2002-12-11T00:00:00Z","timestamp":1039564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2002,12,11]],"date-time":"2002-12-11T00:00:00Z","timestamp":1039564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Neurol"],"published-print":{"date-parts":[[2003]]},"abstract":"<jats:p>Rizatriptan is a selective 5-HT&lt;sub&gt;1B\/1D&lt;\/sub&gt; receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine. This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg\/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy. Of patients expressing a preference (89.1%), more than twice as many preferred rizatriptan to ergotamine\/caffeine (69.9 vs. 30.1%, p \u2264 0.001). Faster relief of headache was the most important reason for preference, cited by 67.3% of patients preferring rizatriptan and 54.2% of patients who preferred ergotamine\/caffeine. The co-primary endpoint of being pain free at 2 h was also in favor of rizatriptan. Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine\/caffeine (p \u2264 0.001), rizatriptan being superior within 1 h of treatment. Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine\/caffeine (p \u2264 0.001), with rizatriptan being superior to ergotamine\/caffeine within 30 min of dosing. Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine\/caffeine (p \u2264 0.001). Rizatriptan was also superior to ergotamine\/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p \u2264 0.001). More patients were (completely, very or somewhat) satisfied 2\u00a0h after treatment with rizatriptan (69.8%) than at 2 h after treatment with ergotamine\/caffeine (38.6%, p \u2264 0.001). Recurrence rates were 31.4% with rizatriptan and 15.3% with ergotamine\/caffeine. Both active treatments were well tolerated. The most common adverse events (incidence \u22675% in one group) after rizatriptan and ergotamine\/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).<\/jats:p>","DOI":"10.1159\/000067018","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T21:05:40Z","timestamp":1050440740000},"page":"20-29","source":"Crossref","is-referenced-by-count":58,"title":["Crossover Comparison of Efficacy and Preference for Rizatriptan 10 mg versus Ergotamine\/Caffeine in Migraine"],"prefix":"10.1159","volume":"49","author":[{"given":"Suzanne","family":"Christie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"G\u00f6bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"France","family":"Vrijens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malathi","family":"Shivaprakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2002,12,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1998.3810737.x"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1998.3804281.x"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000047960"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1999.019006552.x"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159\/000052143"}],"container-title":["European Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/67018","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/67018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:20:52Z","timestamp":1745464852000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000067018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12,11]]},"references-count":5,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2002,12,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000067018","archive":["Portico"],"relation":{},"ISSN":["0014-3022","1421-9913"],"issn-type":[{"value":"0014-3022","type":"print"},{"value":"1421-9913","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,12,11]]}}}